Overview

A class action lawsuit has been filed against Centene Corporation (“Centene” or the “Company”), and certain of the Company’s former senior executive officers alleging violations of the federal securities laws. The Company’s common stock traded on the New York Stock Exchange (the “NYSE”) under the symbol “CNC.”

The Centene class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Centene securities between December 12, 2024, to June 30, 2025, both dates inclusive (the “Class Period”).

Centene describes itself as a leading healthcare enterprise that is committed to helping people live healthier lives. According to Centene, the Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals.

Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace. In 2024, the Company operated in four segments: Medicaid, Medicare, Commercial, and Other.

The Centene class action lawsuit alleges that Defendants provided investors with material information concerning the company’s expected revenue guidance and adjusted diluted EPS for fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s enrollment and morbidity rates, as well as strong retention rates in Centene’s Medicare business.

According to the lawsuit, Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Centene’s enrollment and morbidity rates. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Centene’s securities at artificially inflated prices.

Investors began to question the veracity of Defendants’ public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene’s overall market growth across 22 states, or 72% of the Company’s marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. 5.

Investors and analysts reacted immediately to Centene’s revelation. The price of Centene’s common stock declined dramatically. From a closing market price of $56.65 per share on July 1, 2025, Centene’s stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%.

*          *          *

If you purchased or otherwise acquired Centene securities between December 12, 2024, to June 30, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Centene class action lawsuit is September 8, 2025.